Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for ImmunityBio (IBRX) over the last 6 years, with Dec 2024 value amounting to $700.4 million.

  • ImmunityBio's Shares Outstanding (Diluted Average) rose 35.62% to $946.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.6 million, marking a year-over-year increase of 35.62%. This contributed to the annual value of $700.4 million for FY2024, which is 37.71% up from last year.
  • Per ImmunityBio's latest filing, its Shares Outstanding (Diluted Average) stood at $700.4 million for FY2024, which was up 37.71% from $508.6 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Shares Outstanding (Diluted Average) peaked at $700.4 million during FY2024, and registered a low of $377.1 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $508.6 million (2023), whereas its average is $536.3 million.
  • Data for ImmunityBio's Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 37.71% (in 2024) over the last 5 years.
  • ImmunityBio's Shares Outstanding (Diluted Average) (Yearly) stood at $377.1 million in 2020, then rose by 3.23% to $389.2 million in 2021, then rose by 2.74% to $399.9 million in 2022, then rose by 27.19% to $508.6 million in 2023, then skyrocketed by 37.71% to $700.4 million in 2024.